AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22515905 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl containing 9% (wt/vol) etidronic acid (HEBP)
Number of subjects: 60
Study 22515905 — intervention group
Group type: COMPARATOR
Intervention: 2.5% NaOCl
Number of subjects: 60
Study 20544310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study 18600509 — intervention group
Group type: EXPERIMENTAL
Intervention: urate-lowering agents
Number of subjects: 1832
Study 18600509 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1832
Study 15980629 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 or 7-10 days
Number of subjects: 327
Study 12054164 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy (mean dose, 0.18 IU/kg per week)
Number of subjects: 100
Study 12054164 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontreated)
Number of subjects: 100
Study 12054164 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 100
Study 10472588 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole
Number of subjects: 0
Study 10472588 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7767551 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Atrial Natriuretic Peptide (ANP)
Number of subjects: 10
Study 7767551 — intervention group
Group type: COMPARATOR
Intervention: Thiorphan (NEP inhibitor) alone
Number of subjects: 10
Study 7767551 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Atrial Natriuretic Peptide (ANP) with Thiorphan
Number of subjects: 10
Study 7767551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2181102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral zidovudine therapy (80, 120, or 160 mg/m2/dose, with oral dose being 1.5 times the intravenous dosage)
Number of subjects: 35
Study 7373510 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar partners (homosexual or heterosexual)
Number of subjects: 0
Study 7373510 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterosexual partners
Number of subjects: 0
Study 7373510 — intervention group
Group type: EXPERIMENTAL
Intervention: Homosexual partners
Number of subjects: 0
Study 7373510 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal attitudes
Number of subjects: 0
Study 31800986 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid Conjugate Vaccine (TCV)
Number of subjects: 20019
Study 31800986 — intervention group
Group type: COMPARATOR
Intervention: Capsular group A meningococcal conjugate vaccine (MenA)
Number of subjects: 20019
Study 28376846 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Programme (HeLP)
Number of subjects: 0
Study 28376846 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 0
Study 26359188 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Number of subjects: 108
Study 26359188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal fluocinolone acetonide implant therapy
Number of subjects: 108
Study 26359188 — intervention group
Group type: COMPARATOR
Intervention: Overall (both groups)
Number of subjects: 108
Study 26359188 — intervention group
Group type: COMPARATOR
Intervention: Resolution of macular edema
Number of subjects: 108
Study 26359188 — intervention group
Group type: COMPARATOR
Intervention: Improvement without resolution
Number of subjects: 108
Study 26359188 — intervention group
Group type: COMPARATOR
Intervention: Little to no change
Number of subjects: 108
Study 26359188 — intervention group
Group type: COMPARATOR
Intervention: Worsening
Number of subjects: 108
Study 23426452 — intervention group
Group type: EXPERIMENTAL
Intervention: New Structured Pathway (NSP)
Number of subjects: 231
Study 21270141 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session brief motivational intervention delivered to students
Number of subjects: 0
Study 21270141 — intervention group
Group type: EXPERIMENTAL
Intervention: Handbook-based parent intervention
Number of subjects: 0
Study 21270141 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19476631 — intervention group
Group type: EXPERIMENTAL
Intervention: High antioxidant diet (HAD)
Number of subjects: 83
Study 19476631 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 83
Study 19042478 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert Program
Number of subjects: 12
Study 19042478 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 15677729 — intervention group
Group type: EXPERIMENTAL
Intervention: C34T AMPD1 genotype carriers
Number of subjects: 104
Study 15677729 — intervention group
Group type: EXPERIMENTAL
Intervention: C34T AMPD1 genotype noncarriers
Number of subjects: 104
Study 15677729 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonathletes)
Number of subjects: 104
Study 15677729 — intervention group
Group type: EXPERIMENTAL
Intervention: Athlete group
Number of subjects: 104
Study 11896510 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 156
Study 11896510 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of calcium antagonists
Number of subjects: 156
Study 11896510 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued treatment with calcium antagonists
Number of subjects: 156
Study 10573634 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion formulation (Neoral)
Number of subjects: 23
Study 10573634 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation (Sandimmune)
Number of subjects: 23
Study 7613098 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide
Number of subjects: 2
Study 7613098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 2
Study 2620952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg d-tubocurarine
Number of subjects: 45
Study 2620952 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg succinylcholine
Number of subjects: 45
Study 2620952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 mg/kg pancuronium bromide
Number of subjects: 45
Study 330851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1 gram intramuscularly preoperatively)
Number of subjects: 0
Study 330851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephaloridine (given preoperatively and postoperatively)
Number of subjects: 0
Study 330851 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 0
Study 30725091 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine, 20 mg, 3 times daily (n=27)
Number of subjects: 51
Study 30725091 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=24)
Number of subjects: 51
Study 28346567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Mediterranean Diet (LGIMD)
Number of subjects: 98
Study 28346567 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 98
Study 26267984 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib administered 1 hour before surgery
Number of subjects: 120
Study 26267984 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 1 hour before surgery
Number of subjects: 120
Study 26267984 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 120
Study 22717960 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose-containing smoothie (12 g, 3%)
Number of subjects: 26
Study 22717960 — intervention group
Group type: COMPARATOR
Intervention: Polydextrose-free control smoothie
Number of subjects: 26
Study 20920384 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for educators in four day-care centres
Number of subjects: 252
Study 20920384 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention) in four other day-care centres
Number of subjects: 252
Study 19243946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 13
Study 19243946 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 13
Study 16739544 — intervention group
Group type: EXPERIMENTAL
Intervention: AL irradiation alone at 13.5 joules per square centimeters (0.270 watts, 5‐millimeter beam, 10 seconds)
Number of subjects: 10
Study 16739544 — intervention group
Group type: EXPERIMENTAL
Intervention: RS treatment alone for two minutes
Number of subjects: 10
Study 16739544 — intervention group
Group type: EXPERIMENTAL
Intervention: AL irradiation before RS treatment
Number of subjects: 10
Study 16739544 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 10
Study 15562040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam, 0.1 microg . kg(‐1) . min(‐1)
Number of subjects: 43
Study 15562040 — intervention group
Group type: COMPARATOR
Intervention: Dopamine, 2 microg . kg(‐1) . min(‐1)
Number of subjects: 43
Study 15562040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 43
Study 15562040 — intervention group
Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 43
Study 12092185 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (Zocor) administered to 86% of cases at therapeutic doses for 6 months to one year
Number of subjects: 158
Study 12092185 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 158
Study 9444579 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment based on bedrest for a minimum of two weeks
Number of subjects: 322
Study 9444579 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (no surgery)
Number of subjects: 322
Study 7942489 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise
Number of subjects: 140
Study 7942489 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise
Number of subjects: 140
Study 7942489 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill vs Bicycle exercise
Number of subjects: 140
Study 7942489 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) response to exercise
Number of subjects: 140
Study 2896636 — intervention group
Group type: EXPERIMENTAL
Intervention: levocabastine nasal spray
Number of subjects: 42
Study 2896636 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 31159674 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Aware of Mental Health (YAM) intervention delivered in 78 classes
Number of subjects: 1878
Study 30667510 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback-assisted exercise programme
Number of subjects: 34
Study 30667510 — intervention group
Group type: COMPARATOR
Intervention: Sham electromyographic biofeedback
Number of subjects: 34
Study 28628402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral waters with different concentrations of minerals
Number of subjects: 21
Study 28628402 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 21
Study 28628402 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplement
Number of subjects: 21
Study 26639849 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice flavonoid oil (LFO) 600 mg single dose
Number of subjects: 0
Study 26639849 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice flavonoid oil (LFO) 300 mg repeated ingestion for 8 days
Number of subjects: 0
Study 24273887 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate plus calcitriol (arm C)
Number of subjects: 75
Study 24273887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arm A)
Number of subjects: 75
Study 24273887 — intervention group
Group type: COMPARATOR
Intervention: Calcium gluconate (arm B)
Number of subjects: 75
Study 24273887 — intervention group
Group type: COMPARATOR
Intervention: Placebo or calcium gluconate (arms A and B combined)
Number of subjects: 75
Study 20414685 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of group psychotherapy
Number of subjects: 317
Study 18971536 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily for 24 weeks
Number of subjects: 32
Study 18971536 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily for 24 weeks
Number of subjects: 32
Study 16819695 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic stockinette (E)
Number of subjects: 92
Study 16819695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast padding (C)
Number of subjects: 92
Study 16819695 — intervention group
Group type: COMPARATOR
Intervention: No protective material (N)
Number of subjects: 92
Study 12710221 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory tasks (negative priming, stopping, continuous performance tasks)
Number of subjects: 0
Study 12710221 — intervention group
Group type: COMPARATOR
Intervention: Working memory capacity test
Number of subjects: 0
Study 12710221 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory deficit hypothesis
Number of subjects: 0
Study 10739171 — intervention group
Group type: COMPARATOR
Intervention: Dopamine D2 and D3 receptor gene polymorphisms
Number of subjects: 0
Study 10739171 — intervention group
Group type: COMPARATOR
Intervention: C allele of the TaqIA polymorphism
Number of subjects: 0
Study 9358666 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug antitubercular treatment (group A)
Number of subjects: 25
Study 9358666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 25
Study 1480310 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate (50 mg tablet, 3 times daily for 2 weeks)
Number of subjects: 40
Study 1480310 — intervention group
Group type: COMPARATOR
Intervention: Oxerutin (1,500 mg tablet, 3 times daily for 2 weeks)
Number of subjects: 40
Study 1480310 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate
Number of subjects: 40
Study 1480310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 40
Study 2951198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 to 20 mg at night)
Number of subjects: 14
Study 30636269 — intervention group
Group type: EXPERIMENTAL
Intervention: Real World Evidence (RWE)
Number of subjects: 0
Study 26991772 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg daily for 4 weeks
Number of subjects: 42
Study 26991772 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 42
Study 25155966 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF
Number of subjects: 90
Study 25155966 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO
Number of subjects: 90
Study 25155966 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rhG‐CSF and rhEPO
Number of subjects: 90
Study 25155966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 90
Study 22025228 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological examination by two pathologists
Number of subjects: 678
Study 19833797 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI)
Number of subjects: 32
Study 19833797 — intervention group
Group type: COMPARATOR
Intervention: Diffusion Tensor Imaging (DTI) in patients with preserved speech
Number of subjects: 32
Study 19833797 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI) in nonverbal patients or those speaking only single words
Number of subjects: 32
Study 19833797 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical features correlation
Number of subjects: 32
Study 18490027 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitation of the model's path
Number of subjects: 34
Study 18490027 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous play with goal objects
Number of subjects: 34
Study 15839735 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (song)
Number of subjects: 10
Study 15839735 — intervention group
Group type: EXPERIMENTAL
Intervention: Karaoke accompaniment
Number of subjects: 10
Study 15839735 — intervention group
Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 10
Study 14664673 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VE exploration with a map
Number of subjects: 0
Study 14664673 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VE exploration without a map
Number of subjects: 0
Study 14664673 — intervention group
Group type: COMPARATOR
Intervention: Passive VE training
Number of subjects: 0
Study 14664673 — intervention group
Group type: EXPERIMENTAL
Intervention: VE + map training
Number of subjects: 0
Study 14664673 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a map alone
Number of subjects: 0
Study 10841872 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt
Number of subjects: 60
Study 10841872 — intervention group
Group type: COMPARATOR
Intervention: Large-volume paracentesis
Number of subjects: 60
Study 8815088 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR diagnostic sensitivity for B. pertussis among Chelex-treated aspirates
Number of subjects: 2421
Study 8815088 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR diagnostic sensitivity for B. pertussis among non-Chelex-treated aspirates
Number of subjects: 2421
Study 8815088 — intervention group
Group type: EXPERIMENTAL
Intervention: Final sensitivity after Chelex treatment of PCR-negative samples
Number of subjects: 2421
Study 8815088 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR positive for B. pertussis with culture-negative samples
Number of subjects: 2421
Study 8815088 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR diagnostic sensitivity for B. parapertussis
Number of subjects: 2421
Study 8815088 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional culture-negative B. parapertussis PCR findings
Number of subjects: 2421
Study 1511712 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC regimen (Cisplatin + Cyclophosphamide + Doxorubicin)
Number of subjects: 125
Study 1511712 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC regimen
Number of subjects: 125
Study 1511712 — intervention group
Group type: COMPARATOR
Intervention: PC regimen (Cisplatin + Cyclophosphamide)
Number of subjects: 125
Study 6673080 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal examination every 6 months (Group A)
Number of subjects: 156
Study 6673080 — intervention group
Group type: COMPARATOR
Intervention: Colorectal examination every 24 months (Group B)
Number of subjects: 156
Study 31383985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC)
Number of subjects: 218
Study 31383985 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) chemotherapy alone
Number of subjects: 218
Study 27155856 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated hamstring tendon allograft (Ir‐Allo)
Number of subjects: 112
Study 27155856 — intervention group
Group type: COMPARATOR
Intervention: Non‐irradiated hamstring tendon allograft (Non‐ir‐Allo)
Number of subjects: 112
Study 26421292 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron
Number of subjects: 50
Study 26421292 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg ramosetron
Number of subjects: 50
Study 26421292 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg ramosetron
Number of subjects: 50
Study 23340914 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational sessions with pharmaceutical representatives and counterdetailing sessions by a clinical pharmacist
Number of subjects: 27
Study 23340914 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterdetailing sessions
Number of subjects: 27
Study 23340914 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterdetailing presentations
Number of subjects: 27
Study 22008919 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sevoflurane general and epidural anesthesia (group S1)
Number of subjects: 80
Study 22008919 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sevoflurane general anesthesia (group S2)
Number of subjects: 80
Study 22008919 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined propofol general and epidural anesthesia (group P1)
Number of subjects: 80
Study 22008919 — intervention group
Group type: COMPARATOR
Intervention: Standard propofol general anesthesia (group P2)
Number of subjects: 80
Study 19158371 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1253
Study 19158371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1253
Study 17414930 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients with 18 mg of iron
Number of subjects: 458
Study 17414930 — intervention group
Group type: COMPARATOR
Intervention: Micronutrients without iron (control group)
Number of subjects: 458
Study 15682799 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with 0.2% ropivacaine
Number of subjects: 40
Study 15682799 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion of 0.2% ropivacaine with fentanyl (CEA)
Number of subjects: 40
Study 16316365 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feeding
Number of subjects: 10
Study 16316365 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.86% glucose-based dialysate PD exchange
Number of subjects: 10
Study 10510139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 5 mg twice daily (preschool Caucasians)
Number of subjects: 48
Study 10510139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 10 mg once daily (preschool Caucasians)
Number of subjects: 48
Study 10510139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 10 mg once daily (Caucasian school children)
Number of subjects: 48
Study 10510139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 20 mg once daily (Caucasian school children)
Number of subjects: 48
Study 10510139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 2.5 mg once daily (Oriental preschool children)
Number of subjects: 48
Study 10510139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 5 mg once daily (Oriental preschool children)
Number of subjects: 48
Study 10510139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 10 mg once daily (Oriental school children)
Number of subjects: 48